BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at ValuEngine

BioXcel Therapeutics (NASDAQ:BTAI) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, ValuEngine reports.

A number of other research analysts have also weighed in on BTAI. Zacks Investment Research raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 11th. BMO Capital Markets set a $21.00 price objective on BioXcel Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, HC Wainwright set a $25.00 price objective on BioXcel Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. BioXcel Therapeutics currently has an average rating of “Buy” and an average target price of $19.75.

BioXcel Therapeutics stock opened at $5.30 on Thursday. The stock has a 50-day moving average of $8.42 and a two-hundred day moving average of $9.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.93 and a current ratio of 3.93. BioXcel Therapeutics has a one year low of $2.41 and a one year high of $12.00. The stock has a market cap of $83.38 million, a PE ratio of -4.02 and a beta of 2.96.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.02). As a group, sell-side analysts predict that BioXcel Therapeutics will post -2.22 EPS for the current fiscal year.

In related news, Director Peter Mueller bought 8,446 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were purchased at an average cost of $8.74 per share, with a total value of $73,818.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vimal Mehta bought 2,983 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were bought at an average cost of $8.64 per share, for a total transaction of $25,773.12. The disclosure for this purchase can be found here. Insiders bought 18,976 shares of company stock worth $165,104 over the last three months. Corporate insiders own 64.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Capital Investment Advisory Services LLC acquired a new stake in BioXcel Therapeutics during the second quarter worth about $53,000. Artemis Investment Management LLP grew its holdings in BioXcel Therapeutics by 1.0% during the second quarter. Artemis Investment Management LLP now owns 979,015 shares of the company’s stock worth $10,644,000 after acquiring an additional 10,036 shares during the period. Renaissance Technologies LLC grew its holdings in BioXcel Therapeutics by 59.8% during the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock worth $785,000 after acquiring an additional 26,800 shares during the period. Bank of New York Mellon Corp acquired a new stake in BioXcel Therapeutics during the second quarter worth about $198,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in BioXcel Therapeutics during the second quarter worth about $138,000. 19.05% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

See Also: What is the Dividend Aristocrat Index?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.